A carregar...
Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission....
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3514089/ https://ncbi.nlm.nih.gov/pubmed/23210842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-1-17 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|